Safety and Efficacy of Pre-Cytoreduction Prior to Definitive Multi-Agent Chemotherapy in Aggressive Lymphoma
DOI:
https://doi.org/10.36283/PJMD13-2/009Keywords:
Drug Therapy, Lymphoma, Burkitt LymphomaAbstract
Background: Pre-cytoreduction refers to the administration of initial chemotherapy to reduce tumor burden prior to initiating definitive multi-agent chemotherapy. This study assessed the safety and efficacy of pre-cytoreduction prior to definitive multi-agent chemotherapy in aggressive lymphomas.
Methods: A prospective cohort study was done at Ziauddin Hospital, Karachi for six months. Patients of either gender, aged between 18-80 years diagnosed with aggressive lymphoma (Stage II-IV) were included. Patients having stage-I lymphoma, primary CNS lymphoma, HIV-linked Diffuse Large B Cell Lymphoma (DLBCL) transformed lymphoma, and other malignancies were excluded. The pre-cytoreduction group received a low dose of chemotherapeutic drug on the −6th day and prednisolone 100mg daily for 7 days (−6th day to day 0) followed by standard chemotherapy on day 1. Non-pre-cytoreduction group received chemotherapy without pre-cytoreduction. After chemotherapy's first cycle, follow-up was done for 30 days. Anxiety assessment was done using the Hamilton Anxiety Rating Scale (HAM-A). For data analysis, SPSS v27 was used.
Results: From 120 patients, 27(22.5%) were diagnosed with Burkitt Lymphoma while 93(77.5%) with DLBCL. Pre-cytoreduction included prednisone, in 17(14.2%) patients, while 12(10%), 13(11%), and 10(8%) were given Vincristine, Prednisolone (VP), Cyclophosphamide, Prednisolone (CP) and Cyclophosphamide, Vincristine, and Prednisolone (CVP) respectively. There was a significant difference between both groups’ tumor lysis syndrome, bone marrow suppression, ECOG PS (Eastern Cooperative Oncology Group Performance Status), and other post-treatment complications (p<0.001).
Conclusion: Pre-cytoreduction was reported to be slightly better than conventional therapy in terms of compliance, with pre-cytoreduction improving patients’ performance status, decreased hospital emergency visits, febrile neutropenia risk, and improved treatment response rates.
References
Mugnaini EN, Ghosh N. Lymphoma. Primary Care: Clinics in Office Practice. 2016;43(4):661-675. https://doi.org/10.1016/j.pop.2016.07.012
Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-hodgkin lymphoma. The lancet. 2017 ;390(10091):298-310. https://doi.org/10.1016/S0140-6736(16)32407-2
Aslam W, Habib M, Aziz S. Clinicopathological Spectrum of Hodgkin's and Non-Hodgkin's Lymphoma: A Tertiary Care Cancer Hospital Study in Pakistan. Cureus. 2022 ;14(6) :1-6. DOI: 10.7759/cureus.25620
Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA: a cancer journal for clinicians. 2018;68(2):116-132. https://doi.org/10.3322/caac.21438
Pervez S. Non-hodgkin lymphoma (NHL) in Pakistan. International Journal of Molecular and Cellular Medicine 2012;1(1):62. http://ijmcmed.org/article-1-29-en.html
Lakshmaiah KC, Asati V, Babu K G, Jacob LA, MC SB, KN L, et al. Role of prephase treatment prior to definitive chemotherapy in patients with diffuse large B‐cell lymphoma. European Journal of Haematology. 2018;100(6):644-648. https://doi.org/10.1111/ejh.13068
Malpica L, Mufuka B, Galeotti J, Tan X, Grover N, Clark SM, et al. A retrospective study on prephase therapy prior to definitive multiagent chemotherapy in aggressive lymphomas. Leukemia & lymphoma. 2020;61(6):1508-1511. https://doi.org/10.1080/10428194.2020.1725505
Cencini E, Tucci A, Puccini B, Cavallo F, Luminari S, Usai SV, et al. The elderly prognostic index predicts early mortality in older patients with diffuse large B‐cell lymphoma. An ad hoc analysis of the elderly project by the Fondazione Italiana Linfomi. Hematological Oncology. 2023;41(1):78-87. https://doi.org/10.1002/hon.3081
Schmittlutz K, Marks R. Current treatment options for aggressive non-Hodgkin lymphoma in elderly and frail patients: practical considerations for the hematologist. Therapeutic Advances in Hematology. 2021; 12:2040620721996484. https://doi.org/10.1177/2040620721996484
Wei Y, Yang Q, Qin Q, Chen Y, Quan X, Wei J, et al. Profiling of the Risk Factors and Designing of a Model to Identify Ischemic Stroke in Patients with Non-Hodgkin Lymphoma: A Multicenter Retrospective Study. European Neurology. 2020;83(1):41-48. https://doi.org/10.1159/000506046
Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B‐cell lymphoma in older patients. The Oncologist. 2021 ;26(2):120-132. https://doi.org/10.1002/onco.13610
Gobba SM, Moccia AA, Conconi A, Diem S, Cascione L, von Hohenstaufen KA, et al. Survival and prognostic factors in very elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL): a retrospective analysis of 281 patients over 80 years. Annals of Oncology. 2015; 26:135. https://doi.org/10.1093/annonc/mdv348.11
Eertink JJ, Heymans MW, Zwezerijnen GJ, Zijlstra JM, de Vet HC, Boellaard R. External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prsediction models using PET data from DLBCL patients. EJNMMI research. 2022;12(1):1-8. https://doi.org/10.1186/s13550-022-00931-w
Di M, Huntington SF, Olszewski AJ. Challenges and opportunities in the management of diffuse large B‐cell lymphoma in older patients. The Oncologist. 2021;26(2):120-132. https://doi.org/10.1002/onco.13610
Kesavan M, Eyre TA, Collins GP. Front-line treatment of high-grade B cell non-Hodgkin lymphoma. Current Hematologic Malignancy Reports. 2019; 14:207-218. https://doi.org/10.1007/s11899-019-00518-8
Carrozzino D, Patierno C, Fava GA, Guidi J. The Hamilton rating scales for depression: a critical review of clinimetric properties of different versions. Psychotherapy and psychosomatics. 2020;89(3):133-150. https://doi.org/10.1159/000506879.
King RL, Hsi ED, Chan WC, Piris MA, Cook JR, Scott DW, Swerdlow SH. Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma. Virchows Archiv. 2023;482(1):193-205. https://doi.org/10.1007/s00428-022-03404-6
Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Annals of surgical oncology. 2016; 23:1468-1473. https://doi.org/10.1245/s10434-015-4962-9
Gangireddy M, Shrimanker I, Nookala VK, Peroutka KA. Spontaneous tumor lysis syndrome in diffuse large B-cell lymphoma: early diagnosis and management. Cureus. 2019;11(5). DOI: 10.7759/cureus.4679
Smith SD, Till BG, Shadman MS, Lynch RC, Cowan AJ, Wu QV, et al. A. Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker-driven therapy. British journal of hematology. 2020;189(6):1119-1126. https://doi.org/10.1111/bjh.16494
Turaga KK, Gamblin TC, Alexander HR, Edwards R, Bartlett DL. Regional Therapies for Advanced Cancer: Update for 2016. Annals of Surgical Oncology. 2016; 23:1452-1453. https://doi.org/10.1245/s10434-015-5068-0
Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for" aggressive" lymphoma. Journal of clinical oncology. 2002 ;20(22):4413-4419. DOI: 10.1200/JCO.2002.07.075
Jones SJ, Brooks-Wilson A. Anticipation in multiple-case lymphoid cancer families after controlling for ascertainment biases. Leukemia & Lymphoma. 2021 ;62(13):3147-3151. https://doi.org/10.1080/10428194.2021.1948026
Olszewski AJ, Ollila T, Reagan JL. Time to treatment is an independent prognostic factor in aggressive non‐Hodgkin lymphomas. British journal of hematology. 2018;181(4):495-504. https://doi.org/10.1111/bjh.15224
Zayac AS, Olszewski AJ. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy. Leukemia & lymphoma. 2020;61(8):1784-1796. https://doi.org/10.1080/10428194.2020.1747068
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
